|
Cash and cash equivalents
|
|
$15.4m
|
$15.1m
|
$19.2m
|
$22.7m
|
|
Accounts receivable, net of allowance for credit losses of $6,317 and $3,192 at 2025 and 2024, respectively
|
|
$106.9m
|
$109.4m
|
$111.8m
|
$113.5m
|
|
Inventories
|
|
$60.4m
|
$71.7m
|
$59.4m
|
$54.5m
|
|
Prepaid expenses
|
|
$15.7m
|
$8.2m
|
$10.2m
|
$9.7m
|
|
Income taxes receivable
|
|
$8.2m
|
$13.7m
|
$15.6m
|
$7.3m
|
|
Other current assets
|
|
$5.1m
|
$5.1m
|
$10.5m
|
$6.9m
|
|
TOTAL CURRENT ASSETS
|
|
$211.7m
|
$223.1m
|
$226.6m
|
$214.7m
|
|
PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $320,707 and $314,317 at 2025 and 2024, respectively
|
|
$105.0m
|
$99.6m
|
$97.1m
|
$99.4m
|
|
GOODWILL
|
|
$99.4m
|
$99.4m
|
$99.4m
|
$105.8m
|
|
RIGHT OF USE ASSETS
|
|
$52.4m
|
$53.8m
|
$56.5m
|
$54.3m
|
|
OTHER ASSETS
|
|
$33.7m
|
$34.2m
|
$34.8m
|
$35.3m
|
|
INTANGIBLES, net of accumulated amortization and impairment of $19,531 and $19,326 at 2025 and 2024, respectively
|
|
$7.5m
|
$6.9m
|
$6.4m
|
$7.1m
|
|
DEFERRED TAX ASSETS, net
|
|
$68.6m
|
$69.2m
|
$69.6m
|
$67.4m
|
|
Taxes other than payroll and income
|
|
$4.8m
|
$5.9m
|
$7.1m
|
$4.3m
|
|
Operating lease liabilities
|
|
$11.7m
|
$10.2m
|
$10.7m
|
$11.5m
|
|
Income taxes payable
|
|
$3.0m
|
$7.3m
|
$4.9m
|
$4.3m
|
|
Other current liabilities
|
|
$8.4m
|
$7.7m
|
$8.2m
|
$16.7m
|
|
LONG-TERM OPERATING LEASE LIABILITIES
|
|
$38.3m
|
$42.1m
|
$43.3m
|
$42.3m
|
|
DEFERRED COMPENSATION
|
|
$31.8m
|
$30.5m
|
$31.1m
|
$29.4m
|
|
Preference stock, 6,000,000 shares authorized, $0.01 par value; none issued or outstanding
|
|
0
|
0
|
0
|
0
|
|
Non-controlling interest
|
|
$4.7m
|
$5.0m
|
$5.7m
|
$6.2m
|
|
Total Core Laboratories Inc. shareholders' equity
|
|
$184.3m
|
$224.8m
|
$252.0m
|
$266.0m
|
|
TOTAL EQUITY
|
|
$189.0m
|
$229.8m
|
$257.7m
|
$272.2m
|
|
TOTAL ASSETS
|
|
$578.4m
|
$586.4m
|
$590.4m
|
$584.0m
|
|
Accounts payable
|
|
$45.8m
|
$33.5m
|
$34.5m
|
$37.3m
|
|
Accrued payroll and related costs
|
|
$23.4m
|
$18.8m
|
$22.9m
|
$26.5m
|
|
Unearned revenues
|
|
$5.9m
|
$4.8m
|
$9.3m
|
$5.6m
|
|
TOTAL CURRENT LIABILITIES
|
|
$103.1m
|
$88.1m
|
$97.6m
|
$106.0m
|
|
LONG-TERM DEBT, net
|
|
$172.4m
|
$163.1m
|
$126.1m
|
$110.3m
|
|
DEFERRED TAX LIABILITIES, net
|
|
$22.9m
|
$12.7m
|
$13.8m
|
$8.0m
|
|
OTHER LONG-TERM LIABILITIES
|
|
$20.9m
|
$20.0m
|
$20.7m
|
$15.8m
|
|
Common stock, 200,000,000 shares authorized, $0.01 par value, 46,966,868 issued and 46,095,379 outstanding at 2025; 46,966,868 issued and 46,826,820 outstanding at 2024
|
|
1.2m
|
469k
|
470k
|
470k
|
|
Additional paid-in capital
|
|
$102.3m
|
$110.0m
|
$109.5m
|
$110.2m
|
|
Retained earnings
|
|
$85.9m
|
$120.8m
|
$150.3m
|
$172.7m
|
|
Accumulated other comprehensive income (loss)
|
|
($3.8m)
|
($5.0m)
|
($5.8m)
|
($5.8m)
|
|
Treasury stock (at cost), 871,489 and 140,048 at 2025 and 2024, respectively
|
|
($1.4m)
|
($1.4m)
|
($2.5m)
|
($11.6m)
|
|
TOTAL LIABILITIES AND EQUITY
|
|
$578.4m
|
$586.4m
|
$590.4m
|
$584.0m
|